Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P52803
UPID:
EFNA5_HUMAN
Alternative names:
AL-1; EPH-related receptor tyrosine kinase ligand 7
Alternative UPACC:
P52803
Background:
Ephrin-A5, known alternatively as AL-1 and EPH-related receptor tyrosine kinase ligand 7, plays a pivotal role in neuronal, vascular, and epithelial development. It functions as a cell surface GPI-bound ligand for Eph receptors, facilitating crucial processes such as migration, repulsion, and adhesion through bidirectional signaling. Ephrin-A5's interaction with Eph receptors, including EPHA3 and EPHA2, influences cell-cell adhesion, cytoskeletal organization, lens transparency, axon fasciculation, and glucose-stimulated insulin secretion.
Therapeutic significance:
Understanding the role of Ephrin-A5 could open doors to potential therapeutic strategies, particularly in enhancing neuronal, vascular, and epithelial development, as well as in managing diabetes through the regulation of insulin secretion.